Benralizumab (Fasenra)

Benralizumab (Fasenra) is covered only as add‑on maintenance therapy for patients ≥12 years with severe eosinophilic asthma who have a pretreatment blood eosinophil count ≥300 cells/mcL and remain uncontrolled despite inhaled/oral corticosteroids and other controller medications; off‑label uses are not covered. Approval is for 12 months with dosing of 30 mg q4 weeks ×3 then q8 weeks, and reauthorization requires documentation of baseline eosinophils, prior controller therapy failure, medication administration records, and clinical improvement in asthma control (fewer exacerbations and/or decreased rescue medication use).

"Add-on maintenance treatment of individuals with severe asthma having an eosinophilic phenotype (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.